RYTM (Rhythm Pharmaceuticals) Total Stockholders Equity: $237.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RYTM Rhythm Pharmaceuticals Inc RYTM
56 GF Score
Price $106.60
GF Value $113.09
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Total Stockholders Equity?

Rhythm Pharmaceuticals RYTM +0.48% 56 Total Stockholders Equity is $237.6 Mil as of Mar. 2026. GuruFocus rates RYTM with a GF Score™ of 56/100 and a GF Value™ of $113.09 (Fairly Valued). The stock has 3 warning signs investors should review.

Rhythm Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $237.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Rhythm Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was $1.80. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Rhythm Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.02.

Rhythm Pharmaceuticals  (NAS:RYTM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Rhythm Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(237.616-114.71)/68.445
=1.80

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Rhythm Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.676 + 3.163) / 237.616
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Total Stockholders Equity Related Terms

Rhythm Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Total Stockholders Equity Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 284.15 264.26 169.76 164.55 270.03

Rhythm Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 163.09 133.58 295.68 270.03 237.62
RYTM
56GF Score
Rhythm Pharmaceuticals Inc RYTM
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $237.6 Mil mean?
Rhythm Pharmaceuticals (RYTM) has a Total Stockholders Equity of $237.6 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Total Stockholders Equity too high?
Rhythm Pharmaceuticals' current Total Stockholders Equity is $237.6 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Total Stockholders Equity compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Total Stockholders Equity of $237.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Total Stockholders Equity is $237.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Fairly Valued. The stock's GF Value™ is $113.09, compared to a current price of $106.60 — trading 5.7% below its estimated fair value. The current Total Stockholders Equity is $237.6 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Total Stockholders Equity is $237.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of $106.60 is trading 5.7% below its estimated GF Value™ of $113.09. GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.

Key valuation signals for RYTM:

  • Total Stockholders Equity: $237.6 Mil
  • GF Value™: $113.09 vs. price of $106.60 (5.7% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges 1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score

Get the complete analysis for RYTM

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$106.60
Price
$113.09
GF Value